NHS England Commercial Medicines Team
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use
An estimated 1.2 million people in the US are currently living with the virus
Gilead Sciences and Kymera enter oncology partnership worth up to $750m
The companies will focus on advancing Kymera’s oral molecular glue degrader programme
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval
More than 100 people in the US were diagnosed with HIV every day in 2023
Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC
Primary biliary cholangitis affects approximately 163,000 people in Europe
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults
The company gained access to the drug through its $4.3bn acquisition of CymaBay
Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn
Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients
Gilead appoints Dietmar Berger as chief medical officer
Berger most recently served as chief medical officer and global head of development at Sanofi
Gilead and AI-focused Genesis partner to develop small molecule therapies
The companies will use Genesis’ AI platform to generate and optimise molecules for targets selected by Gilead
Gilead shares positive phase 3 results for twice-yearly HIV PrEP drug in women
Lenacapavir demonstrated 100% efficacy in protecting more than 2,000 women against the infection
Gilead’s investigational seladelpar shows promise in primary biliary cholangitis
The company gained access to the candidate through its $4.3bn acquisition of CymaBay in March
Gilead’s Veklury receives NICE recommendation to treat COVID-19 in vulnerable adults and children
Veklury is now the first antiviral recommended by the agency to treat eligible children
Gilead and NHS England extend collaboration to eliminate hepatitis C by 2025
The blood-borne disease is estimated to affect around 62,600 people in England